CISCRP Announces Updated Version of Patient and Family Clinical Trials Guide
The Gift of Participation, a guide for patients and family about the clinical trials has been updated to include new information.
The Center for Information & Study on Clinical Research Participation (CISCRP) has announced the updated version of The Gift of Participation is now available. 'The Gift' was written as a guide for patients and their families considering participation in clinical trials. It was also written as a resource for professionals to use when discussing the clinical research process with their patients and the public. This new edition contains updated chapters and includes new material about social media use in clinical trials; the Sunshine Act and new laws about clinical trials data disclosure and transparency.
During the past five years, more than 200,000 copies of the first edition have been purchased and distributed. All of the proceeds from the book's sales are donated to CISCRP to support its public education and outreach initiatives.
Click here for more information or to order the book.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
